<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00335478</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000476568</org_study_id>
    <secondary_id>OHSU-CPC-05052-L</secondary_id>
    <secondary_id>OHSU-1321</secondary_id>
    <secondary_id>CUBIST-OHSU-CPC-05052-L</secondary_id>
    <nct_id>NCT00335478</nct_id>
  </id_info>
  <brief_title>Daptomycin in Treating Neutropenia and Fever in Patients With Cancer</brief_title>
  <official_title>Phase II Open Label Pilot Trial of Empiric Daptomycin Treatment for Oncology Patients With Neutropenic Fever</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OHSU Knight Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>OHSU Knight Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Antibiotics, such as daptomycin, may control neutropenia, fever, and infection in
      patients with cancer.

      PURPOSE: This phase II trial is studying how well daptomycin works in treating neutropenia
      and fever in patients with cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Assess the response rate to therapy within 72 hours of starting daptomycin in cancer
           patients with neutropenic fever.

      Secondary

        -  Assess the percentage of bacterial cures in patients with documented gram-positive
           bacterial infections.

        -  Assess time to afebrile state.

        -  Assess the pharmacokinetic data of daptomycin in neutropenic patients.

        -  Document the incidence of breakthrough infections that require a change of therapy or
           additional agents to clear.

        -  Assess the tolerability of daptomycin in neutropenic patients.

        -  Assess and document adverse events and toxicity due to daptomycin.

      OUTLINE: This is an open-label, pilot study.

      Patients first receive standard treatment for gram-negative bacteria for 72 hours. If the
      patient is still febrile at 72 hours, daptomycin is administered.

      Patients receive daptomycin IV over 30 minutes once daily. Patients who are afebrile, not
      neutropenic (absolute neutrophil count [ANC] &gt; 500/mm³), and have no signs of infection after
      72 hours of therapy may discontinue daptomycin. Patients who are afebrile and neutropenic
      (ANC &lt; 500/mm³) after 72 hours of therapy continue to receive daptomycin until absolute
      neutrophil count (ANC) &gt; 500/mm³ for 2 consecutive days. Patients who are febrile with or
      without continued neutropenia (ANC &lt; 500/mm³) after 72 hours of therapy continue to receive
      daptomycin for up to 10-14 days in the absence of unacceptable toxicity.

      PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Who Became Afebrile Within 72 Hours of Starting Daptomycin.</measure>
    <time_frame>Within 72 hours of starting daptomycin</time_frame>
    <description>If after 72 hours of daptomycin treatment, the patient is afebrile and has absolute neutrophil count (ANC) &gt;500 cells/mm^3 for 48 hours with no site of infection, negative cultures, and no clinical indications for therapy, the antibiotic regimen will be discontinued.
Complete Response: Resolution of fever and clinical signs/symptoms of infection.
Partial Response: Resolution of fever without resolution of clinical signs of infection.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Fever</condition>
  <condition>Sweating</condition>
  <condition>Hot Flashes</condition>
  <condition>Infection</condition>
  <condition>Neutropenia</condition>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>Daptomycin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daptomycin</intervention_name>
    <description>daptomycin 6 mg/kg over 30 minutes every 24 hours until patient is afebrile and ANC is &gt;500 cells/mm^3.</description>
    <arm_group_label>Daptomycin</arm_group_label>
    <other_name>Cubicin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosis of cancer

          -  Diagnosis of neutropenic fever

               -  Temperature &gt; 38.3°C once OR ≥ 38°C twice within 12 hours

               -  Absolute neutrophil count &lt; 500/mm^³ and ≥ 1 of the following:

                    -  Mucositis

                    -  Concurrent skin or soft tissue infection

                    -  Indwelling catheter and/or suspected catheter infection

                    -  Recent quinolone prophylaxis

                    -  Positive blood cultures for gram-positive cocci before final identification
                       or other documented gram-positive pathogen

                    -  Colonization with β-lactam resistant gram-positive organisms (commonly the
                       nares or the skin)

                    -  Hypotension, tachycardia, narrowed pulse pressures, tachypnea, or other
                       signs of cardiovascular compromise

               -  Expected duration of neutropenia ≥ 3 days

          -  No known infection with daptomycin-resistant organism or gram-negative organism and
             not yet meeting criteria for the addition of gram-positive antimicrobial therapy

          -  No suspected meningitis or osteomyelitis

          -  No documented or suspected gram-positive pneumonia

          -  No suspected or proven endocarditis

        PATIENT CHARACTERISTICS:

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2

          -  Life expectancy ≥ 2 weeks

          -  Creatinine clearance ≥ 50 mL/min

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective double-method contraception

          -  No known sensitivity to daptomycin or product excipients

          -  No history of or concurrent rhabdomyolysis

          -  No HIV positivity

          -  No psychiatric disorders that would preclude study compliance

          -  No signs or symptoms of myopathy with creatine phosphokinase (CPK) elevation &gt; 1,000
             U/L (5 times upper limit of normal [ULN])

               -  No CPK elevations &gt; 10 times ULN in patients with no signs or symptoms of
                  myopathy

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  At least 7 days since prior daptomycin or other antibiotic agents covering
             gram-positive organisms

          -  No concurrent hemodialysis or continuous ambulatory peritoneal dialysis

          -  No concurrent succinylcholine, ethanol, fludrocortisone, olanzapine, or pioglitazone

          -  No concurrent hydroxymethyl glutaryl (HMG) coenzyme A (HMG CoA) reductase inhibitors
             (e.g., lovastatin, simvastatin, atorvastatin)

          -  Concurrent therapy for gram-negative bacterial infection allowed
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph Bubalo, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>OHSU Knight Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>OHSU Knight Cancer Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 8, 2006</study_first_submitted>
  <study_first_submitted_qc>June 8, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2006</study_first_posted>
  <results_first_submitted>June 7, 2011</results_first_submitted>
  <results_first_submitted_qc>July 12, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 9, 2011</results_first_posted>
  <last_update_submitted>May 7, 2017</last_update_submitted>
  <last_update_submitted_qc>May 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>OHSU Knight Cancer Institute</investigator_affiliation>
    <investigator_full_name>Joseph Bubalo</investigator_full_name>
    <investigator_title>PharmD</investigator_title>
  </responsible_party>
  <keyword>neutropenia</keyword>
  <keyword>infection</keyword>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <keyword>fever, sweats, and hot flashes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fever</mesh_term>
    <mesh_term>Neutropenia</mesh_term>
    <mesh_term>Hot Flashes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Daptomycin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Daptomycin</title>
          <description>6 mg/kg over 30 minutes every 24 hours until patient is afebrile and ANC is &gt;500 cells/mm^3.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Daptomycin</title>
          <description>6 mg/kg over 30 minutes every 24 hours until patient is afebrile and ANC is &gt;500 cells/mm^3.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.4" spread="16.730"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Became Afebrile Within 72 Hours of Starting Daptomycin.</title>
        <description>If after 72 hours of daptomycin treatment, the patient is afebrile and has absolute neutrophil count (ANC) &gt;500 cells/mm^3 for 48 hours with no site of infection, negative cultures, and no clinical indications for therapy, the antibiotic regimen will be discontinued.
Complete Response: Resolution of fever and clinical signs/symptoms of infection.
Partial Response: Resolution of fever without resolution of clinical signs of infection.</description>
        <time_frame>Within 72 hours of starting daptomycin</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Daptomycin</title>
            <description>6 mg/kg over 30 minutes every 24 hours until patient is afebrile and ANC is &gt;500 cells/mm^3.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Became Afebrile Within 72 Hours of Starting Daptomycin.</title>
          <description>If after 72 hours of daptomycin treatment, the patient is afebrile and has absolute neutrophil count (ANC) &gt;500 cells/mm^3 for 48 hours with no site of infection, negative cultures, and no clinical indications for therapy, the antibiotic regimen will be discontinued.
Complete Response: Resolution of fever and clinical signs/symptoms of infection.
Partial Response: Resolution of fever without resolution of clinical signs of infection.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Daptomycin</title>
          <description>6 mg/kg over 30 minutes every 24 hours until patient is afebrile and ANC is &gt;500 cells/mm^3.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Joseph Bubalo, PharmD, BCPS, BCOP</name_or_title>
      <organization>OHSU Knight Cancer Institute</organization>
      <phone>503-494-1080</phone>
      <email>bubaloj@ohsu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

